SCHEMBL23717075

SCHEMBL23717075

CCc1cc(OC)c2cnccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.57
PTGS2 P35354 1/20 0.47
PDE10A Q9Y233 4/20 0.42
LMNA P02545 3/20 0.42
USP2 O75604 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 2/20 0.42
MAPK1 P28482 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HIF1A Q16665 2/20 0.42
PDE3B Q13370 2/20 0.42
PDE3A Q14432 2/20 0.42
PDE2A O00408 1/20 0.42
ABCC4 O15439 1/20 0.42
PDE5A O76074 1/20 0.42
ABCB11 O95342 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411993 0.79 MAOA (0.60) MAOAPDE10AALDH1A1CYP3A4MAPK1
SCHEMBL19663000 0.79 MAOA (0.40) MAOAALDH1A1SMN1; SMN2ACHERAB9A
SCHEMBL29831723 0.79 MAOA (0.60) MAOAPDE10AALDH1A1CYP3A4MAPK1
SCHEMBL11176425 0.78 MAOA (0.58) MAOAALDH1A1CYP3A4MAPK1SMN1; SMN2
SCHEMBL23166970 0.78 MAOA (0.58) MAOAPDE10ALMNAUSP2ALDH1A1
SCHEMBL29923831 0.78 MAOA (0.39) MAOAALDH1A1SMN1; SMN2ACHECREBBP
SCHEMBL23717076 0.77 PTGS2 (0.52) PTGS2PDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL24510994 0.77 PTGS2 (0.52) PTGS2PDE10ALMNAALDH1A1SMN1; SMN2
SCHEMBL21237375 0.75 HSPA5 (0.39) MAOAALDH1A1SMN1; SMN2RAB9ACREBBP
SCHEMBL23717022 0.75 MAOA (0.55) MAOAALDH1A1CYP3A4MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420976-B2 Heterocyclic compounds as anti-viral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-08-23 US disclosed
US-20210238188-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238188-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN MAOA 2105/4885PTGS2 400/4885PDE10A 2051/4885
US-11420976-B2 Heterocyclic compounds as anti-viral agents VIP, ACE, FURIN MAOA 2105/4885PTGS2 400/4885PDE10A 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.